World Health Organization. (2019). ICD-10: International Statistical Classification of Diseases and Related Health Problems, 10th Revision. Geneva: WHO.
[2]
Antman, K., & Chang, Y. (2000). Kaposi's sarcoma. New England Journal of Medicine, 342(14), 1027-1038.
[3]
Schwartz, R. A., Micali, G., Nasca, M. R., & Scuderi, L. (2008). Kaposi sarcoma: a continuing conundrum. Journal of the American Academy of Dermatology, 59(2), 179-206.
[4]
Kaposi, M. (1872). Idiopathisches multiples Pigmentsarkom der Haut. Archiv für Dermatologie und Syphilis, 4(2), 265-273.
[5]
Cesarman, E., Damania, B., Krown, S. E., Martin, J., Bower, M., & Whitby, D. (2019). Kaposi sarcoma. Nature Reviews Disease Primers, 5(1), 9.
[6]
Bower, M., Collins, S., Cottrill, C., Cwynarski, K., Fountain, H., Gabe, S., ... & Williams, M. (2006). British HIV Association guidelines for HIV-associated malignancies 2006. HIV Medicine, 7(8), 508-523.
[7]
Gao, S. J., Kingsley, L., Hoover, D. R., Spach, D. H., Detels, R., Parry, P., ... & Chang, Y. (1996). Seroconversion to antibodies against Kaposi's sarcoma-associated herpesvirus-related latent nuclear antigens before the development of Kaposi's sarcoma. New England Journal of Medicine, 335(4), 233-241.
[8]
Pantanowitz, L., & Dezube, B. J. (2008). Advances in the pathophysiology and treatment of HIV-associated Kaposi sarcoma. Advances in Oncology, 24(2), 255-267.